Program
valbenazine
Also written as “Valbenazine”, “NBI-98854” and “MT-5199”.
Its studies are mostly in Tardive Dyskinesia · Tourette Syndrome · Schizophrenia · Huntington Disease · Dyskinesias, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Neurocrine Biosciences | 272 open or running | phase 4since Oct 4, 2018 | Dec 21, 2010 | Apr 2028phase 3 · NCT06312189 |
| Tanabe Pharma | 10 open or running | phase 3since Jun 2, 2017 | Jun 2, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 15 studies since Dec 21, 2010.
- Feb 19, 2018Phase 2 study in Tourette SyndromeNeurocrine Biosciences · NCT03444038 · 85 enrolled · United States, Puerto Rico
- May 8, 2018Phase 2 study in Tourette SyndromeNeurocrine Biosciences · NCT03530293 · 81 enrolled · United States, Puerto Rico
- Oct 4, 2018Phase 4 study in Tardive DyskinesiaNeurocrine Biosciences · NCT03698331 · 89 enrolled · United States, Puerto Rico
- Nov 5, 2018Phase 2 study in Tourette SyndromeNeurocrine Biosciences · NCT03732534 · 6 enrolled · United States, Puerto Rico
- Mar 25, 2019Phase 4 study in Tardive DyskinesiaNeurocrine Biosciences · NCT03891862 · 135 enrolled · United States, Puerto Rico
- Sep 23, 2019Phase 3 study in Huntington DiseaseNeurocrine Biosciences · NCT04102579 · 128 enrolled · United States, Canada
- May 19, 2020Phase 3 study in Huntington DiseaseNeurocrine Biosciences · NCT04400331 · 154 enrolled · United States, Canada
- Oct 26, 2021Phase 3 study in SchizophreniaNeurocrine Biosciences · NCT05110157 · 442 enrolled · United States, Argentina, Bulgaria and more
- Jan 10, 2022Phase 3 study in DyskinesiasNeurocrine Biosciences · NCT05206513 · 86 enrolled · United States, Argentina, Belgium and more
- Dec 8, 2022Phase 3 study in SchizophreniaNeurocrine Biosciences · NCT05654870 · 8 enrolled · United States
- May 5, 2023Phase 4 study in SchizophreniaNeurocrine Biosciences · NCT05859698 · 59 enrolled · United States
- Mar 8, 2024Phase 3 study in Huntington DiseaseNeurocrine Biosciences · NCT06312189 · 7 planned · Canada
- Jul 29, 2025Phase 4 study in SchizophreniaNeurocrine Biosciences · NCT07105111 · 100 planned · United States
- Nov 3, 2026Phase 3 study terminatedStudy stoppedNCT04400331 · “Sponsor Decision”
Ahead
- Apr 2028Primary completion: phase 3 study in Huntington DiseaseNeurocrine Biosciences · NCT06312189
- Jun 2028Primary completion: phase 4 study in SchizophreniaNeurocrine Biosciences · NCT07105111
TargetBeta
“Synaptic vesicular amine transporter inhibitor; Synaptic vesicular amine transporter inhibitor”ChEMBL 37, by rule
Other programs on SLC18A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lisdexamfetaminerule | Takeda | phase 4 | 47 |
| deutetrabenazinerule | Teva Pharmaceutical Industries | phase 4 | 12 |
Studies
All 28 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07105111Schizophrenia · United States | 4 | Recruiting | Neurocrine Biosciences | Jun 2028 | 100 |
| NCT06312189Huntington Disease · Canada | 3 | By invitation | Neurocrine Biosciences | Apr 2028 | 7 |
| NCT05859698Schizophrenia · United States | 4 | Completed | Neurocrine Biosciences | Dec 27, 2024 | 59 |
| NCT05654870Schizophrenia · United States | 3 | Terminated | Neurocrine Biosciences | Nov 8, 2023 | 8 |
| NCT05206513Dyskinesias · United States, Argentina, Belgium and more | 3 | Completed | Neurocrine Biosciences | Oct 16, 2025 | 86 |
| NCT05110157Schizophrenia · United States, Argentina, Bulgaria and more | 3 | Completed | Neurocrine Biosciences | Feb 4, 2025 | 442 |
| NCT04400331Huntington Disease · United States, Canada | 3 | Terminated | Neurocrine Biosciences | Nov 5, 2025 | 154 |
| NCT04102579Huntington Disease · United States, Canada | 3 | Completed | Neurocrine Biosciences | Oct 15, 2021 | 128 |
| NCT03891862Tardive Dyskinesia · United States, Puerto Rico | 4 | Completed | Neurocrine Biosciences | Dec 23, 2019 | 135 |
| NCT03732534Tourette Syndrome · United States, Puerto Rico | 2 | Terminated | Neurocrine Biosciences | Feb 18, 2019 | 6 |
| NCT03698331Tardive Dyskinesia · United States, Puerto Rico | 4 | Completed | Neurocrine Biosciences | Apr 3, 2019 | 89 |
| NCT03530293Tourette Syndrome · United States, Puerto Rico | 2 | Terminated | Neurocrine Biosciences | Jul 16, 2019 | 81 |
| NCT03444038Tourette Syndrome · United States, Puerto Rico | 2 | Completed | Neurocrine Biosciences | Jul 12, 2019 | 85 |
| NCT03325010Tourette Syndrome · United States, Puerto Rico | 2 | Completed | Neurocrine Biosciences | Nov 1, 2018 | 127 |
| NCT03176771Tardive Dyskinesia · Japan | 3 | Completed | Tanabe Pharma | Sep 29, 2020 | 256 |
| NCT02879578Tourette Syndrome · United States | 2 | Completed | Neurocrine Biosciences | Nov 1, 2017 | 155 |
| NCT02736955Tardive Dyskinesia · United States | 3 | Completed | Neurocrine Biosciences | Jun 30, 2017 | 161 |
| NCT02679079Tourette Syndrome · United States | 2 | Completed | Neurocrine Biosciences | Apr 14, 2017 | 98 |
| NCT02581865Tourette Syndrome · United States | 2 | Completed | Neurocrine Biosciences | Dec 2016 | 124 |
| NCT02405091Tardive Dyskinesia · United States, Canada, Puerto Rico | 3 | Completed | Neurocrine Biosciences | Mar 2017 | 167 |
| NCT02274558Tardive Dyskinesia · United States, Canada, Puerto Rico | 3 | Completed | Neurocrine Biosciences | Sep 2015 | 234 |
| NCT02256475Tourette Syndrome · United States | 1 | Completed | Neurocrine Biosciences | Nov 2015 | 36 |
| NCT01916993Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects · United States | 1 | Completed | Neurocrine Biosciences | Dec 2013 | 24 |
| NCT01910480Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects · United States | 1 | Completed | Neurocrine Biosciences | Aug 2013 | 24 |
| NCT01733121Tardive Dyskinesia · United States, Puerto Rico | 2 | Completed | Neurocrine Biosciences | Dec 2013 | 102 |
| NCT01688037Tardive Dyskinesia · United States, Puerto Rico | 2 | Completed | Neurocrine Biosciences | Sep 2013 | 109 |
| NCT01393600Tardive Dyskinesia · United States | 2 | Completed | Neurocrine Biosciences | Feb 2012 | 37 |
| NCT01267188Tardive Dyskinesia · Canada | 2 | Completed | Neurocrine Biosciences | Mar 2011 | 10 |
How it is read
Names in the registry
- “Valbenazine”, 15 entries
- “NBI-98854”, 13 entries
- “MT-5199”, 1 entry
- “NBI-98854 50 mg capsule”, 1 entry
- “NBI-98854 50 mg capsule once daily”, 1 entry
Conditions, from the studies’ own filings
- Tardive Dyskinesia, 10 studies
- Tourette Syndrome, 8 studies
- Schizophrenia, 4 studies
- Huntington Disease, 3 studies
- Dyskinesias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.